Interested in specific subtype?

Filter what you see here

CLL/SLL

Quick poll

FDA approval of acalabrutinib for adult patients with CLL or SLL

FDA approval of acalabrutinib for adult patients with CLL or SLL

Closes Nov 27, 2019

PTCL

Quick poll

Phase I study of oral 5-azacytidine and romidepsin in patients with PTCL

Closes Nov 21, 2019

CLL/SLL

Quick poll

A 17-gene expression signature to distinguish patients who are likely to…

Closes Nov 20, 2019

HL

Quick poll

Response-adapted therapy of stage III-IV Hodgkin lymphoma using PET…

Response-adapted therapy of stage III-IV Hodgkin lymphoma using PET imaging: a five-year follow-up of the SWOG S0816 trial

Closes Nov 19, 2019

DLBCL

Quick poll

CHMP recommends EMA approval of polatuzumab vedotin for the treatment of…

Closes Nov 19, 2019

FL

Quick poll

Lenalidomide plus rituximab receives CHMP’s positive opinion for the…

Closes Nov 18, 2019

MCL

Quick poll

FDA approves zanubrutinib for the treatment of adult patients with R/R MCL

FDA approves zanubrutinib for the treatment of adult patients with R/R MCL

Closes Nov 15, 2019

EBV-TCL

Quick poll

Nanatinostat plus valganciclovir granted Fast Track designation by…

Closes Nov 13, 2019

DLBCL,   CLL/SLL,  FL,  MCL,  MZL

Quick poll

CD19/CD22-targeted CAR T therapy for relapsed/refractory B-cell…

Closes Nov 12, 2019

DLBCL

Quick poll

T cell antigen coupler (TAC) therapy - TAC01-CD19 - granted Fast Track…

T cell antigen coupler (TAC) therapy - TAC01-CD19 - granted Fast Track designation by the FDA for the treatment of patients with R/R DLBCL

Closes Nov 11, 2019

PTCL,   CLL/SLL,  FL,  HL,  MCL,  MZL

Quick poll

Educational theme: Prognostic factors in lymphoma

Closes Nov 5, 2019

DLBCL,   CLL/SLL

Quick poll

Impact of donor type on outcomes of allogeneic transplant

Closes Nov 1, 2019

CLL/SLL,   DLBCL,  FL,  MCL,  MZL

Quick poll

Ublituximab and umbralisib for R/R B-cell NHL and CLL/SLL

Ublituximab and umbralisib for R/R B-cell NHL and CLL/SLL

Closes Nov 1, 2019

HGBL

Quick poll

IHC algorithm reliably predicts GATA3 and TBX21 subtypes of PTCL-NOS

Closes Oct 31, 2019

CLL/SLL

Quick poll

Phase II trial CLARITY demonstrates efficacy and safety of ibrutinib plus…

Closes Oct 28, 2019
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (CLL)

Latest Medical Information

Latest Biology

PTCL,CLL/SLL,FL,HL,MCL,MZL

Educational theme: Prognostic factors in lymphoma

Nov 5, 2019

Latest Drug Updates

ASCO 2019

Recently updated Licenses

Where we are next

61st ASH Annual Meeting & Exposition

December 7-10, 2019| Orange County Convention Center (OCCC), Orlando, FL

The Lymphoma Hub will be attending the 61st ASH Annual Meeting & Exposition Orlando, FL. We will be presenting live coverage via our social media channels, interviewing world-leading experts and providing summaries of key sessions. Stay tuned to follow our first-hand coverage.

#lymsm

Event Website

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology